BCR/ABL-transformed chronic myeloid leukemia (CML) cells accumulate numerous DNA double-strand breaks (DSB) induced by reactive oxygen species (ROS) and genotoxic agents. To repair these lesions BCR/ABL stimulate unfaithful DSB repair pathways, homologous recombination repair (HRR), nonhomologous endjoining (NHEJ), and single-strand annealing (SSA). Here, we show that BCR/ABL enhances the expression and increase nuclear localization of WRN (mutated in Werner syndrome), which is required for processing DSB ends during the repair. Other fusion tyrosine kinases (FTK), such as TEL/ABL, TEL/JAK2, TEL/PDGFbR, and NPM/ ALK also elevate WRN. BCR/ABL induces WRN mRNA and protein expression in part by c-MYC-mediated activation of transcription and Bcl-xL-dependent inhibition of caspase-dependent cleavage, respectively. WRN is in complex with BCR/ABL resulting in WRN tyrosine phosphorylation and stimulation of its helicase and exonuclease activities. Activated WRN protects BCR/ABL-positive cells from the lethal effect of oxidative and genotoxic stresses, which causes DSBs. In addition, WRN promotes unfaithful recombination-dependent repair mechanisms HRR and SSA, and enhances the loss of DNA bases during NHEJ in leukemia cells. In summary, we postulate that BCR/ABL-mediated stimulation of WRN modulates the efficiency and fidelity of major DSB repair mechanisms to protect leukemia cells from apoptosis and to facilitate genomic instability.
Introduction
Chromosomal translocations are responsible for the appearance of oncogenes encoding fusion tyrosine kinases (FTK), such as BCR/ABL, TEL/ABL, TEL/JAK2, TEL/PDGFbR, and NPM/ALK, which induce hematologic malignancies, such as chronic myeloproliferative disorders (MPD), acute leukemias and lymphomas (1) . For example, BCR/ABL kinase transforms hematopoietic stem cells to induce chronic myeloid leukemia in chronic phase (CML-CP; ref. 2) . However, CML-CP eventually progresses to highly malignant blast phase (CML-BP) due to enhanced chromosomal instability (3) .
FTKs also enhance DNA damage caused by reactive oxygen species (ROS) and genotoxic agents, and modulate the efficiency and fidelity of DNA repair mechanisms to promote resistance to genotoxic stress and genomic instability (3) . We, and others found that leukemia cells expressing BCR/ABL (including CML-CP stem/progenitor cells enriched population) and other FTKs may contain elevated numbers of DNA double-strand breaks (DSB) caused by ROS and genotoxic treatment; repair of these DSBs is accelerated but the fidelity of repair mechanisms (homologous recombination repair ¼ HRR, nonhomologous end-joining ¼ NHEJ, and single-strand annealing ¼ SSA) is compromised (4) (5) (6) (7) (8) (9) .
Unwinding and exonucleolytic degradation of DSBs by RecQ-like helicase family members is required for the initiation and resolution of the DSBs repair intermediates (10) . The RecQ-like helicase family consists of 5 known proteins: BLM, WRN, RTS, RECQL1, and RECQL5, which aberrant regulation has been detected in tumors.
WRN helicase/exonuclease seems to play a role in carcinogenesis and promotion of tumor cell growth (10) . Werner syndrome (WS) is caused by WRN mutations generating truncated proteins that either fail to localize to the nucleus or destabilize the protein, thus affecting DNA repair. WS is associated with premature senescence and higher incidence of cancers probably due to accumulation of DNA lesions and chromosomal instability. On the other hand upregulation of nonmutated WRN in numerous types of tumors (fibrosarcoma, ovarian cancer, glioma, glioblastoma, fibrosarcoma, colon carcinoma, cervical carcinoma, bladder carcinoma, renal cell carcinoma) and in cells transformed by oncogenic viruses, such as SV40 T-antigen or Epstein-Barr virus, promoted proliferation and survival after genotoxic treatment (11) (12) (13) . Therefore, WRN can exert a tumor-suppressor and tumor-promoting function. In concordance, WRN may change the balance between carcinogenesis versus senescence caused by c-Myc oncogenic stimulation (14) .
Here we report that BCR/ABL-mediated regulation of WRN stimulates all 3 unfaithful DSB repair mechanisms, HRR, NHEJ, and SSA, which promote survival and genomic instability in leukemia cells. Therefore, WRN may play a key role in accumulation of additional chromosomal aberrations to facilitate malignant progression of CML.
Methods

Cells
FL5.12, 32D, and BaF3 murine parental hematopoietic cells, MO7 and UT7 human megakaryoblastic cell lines, and their counterparts transformed with p210BCR/ABL, TEL/JAK2, TEL/PDGFRB, TEL/ABL, and NPM/ALK were used before (5, 15, 16) and maintained in Iscove's modified defined medium (IMDM) supplemented with 1 mmol/L glutamine, 10% FBS and interleukin 3 (IL-3)-conditioned medium (murine cells), or stem cell factor (SCF)-conditioned medium and recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF; PeproTech Inc.) in the concentrations necessary to support cell proliferation. The 32D cells overexpressing Bcl-xL were described before (5 Semiquantitative RT-PCR WRN expression was examined by semiquantitative RT-PCR simultaneously detecting WRN and GADPH (internal reaction control) in total RNA as described before (17) with modifications (Supplemental Methods).
DNA constructs
pSRa-p210BCR/ABL and pMig retroviral plasmids containing IRES-GFP only, BCR/ABL wild-type-IRES-GFP, BCR/ABL kinase-deficient mutant (K1172R)-IRES-GFP, or BCR/ABL-IRES-YFP were obtained from Drs. Charles Sawyers (UCLA, Los Angeles, CA), Warren Pear (University of Pennsylvania, Philadelphia, PA), and Bruno Calabretta (Thomas Jefferson University, Philadelphia, PA). LXSN retroviral construct containing the full-length wild-type human WRN cDNA was from Dr. Junko Oshima (University of Washington, Seattle, WA). pBABEpuro-shWRN retroviral plasmid encoding for anti-WRN harpin corresponding to human WRN cDNA bps 391-415 was kindly provided by Dr. Raymond J. Monnat (University of Washington, Seattle, WA) and modified by replacing the puromycin resistance gene with a zeocin cDNA between HindIII and ClaI sites (18) . WRN promoter region (nucleotides À573 to þ160 of WRN mRNA; GenBank/EMBL Data Bank accession no. AB003173; ref. 18 ) was amplified by PCR and cloned at the MluI and BglII sites of the pGL3 luciferase reporter vector (Promega) to generate pGL3-WRN-luc reporter plasmid. pSRaMSVtkneo empty plasmid or that containing 2 different dominant negative mutants (DNM) of c-Myc: (D106-143) or In373 were obtained from Dr. Sawyers. pMXpuro STAT5B-DNM was described before (16) .
Inhibitors
Imatinib was obtained from Novartis Pharma AG, Z-VAD-FMK was purchased from Bachem AG, and epoxomycin was from Biomol (Plymouth Meeting).
WRN transactivation assay
The assay was carried out as previously described (5 
Immunoprecipitation and Western analysis
Total and nuclear cell lysates were obtained as described before (16, 19) . To detect WRN phosphorylation cells were preincubated with 100 mmol/L pervanadate for 5 minutes in serum-free medium (20) . Chromatin fractions were prepared by sonication of the insoluble nuclear pellets. Protein lysates and immunoprecipitates were resolved by SDS-PAGE followed by Western analysis using the antibodies specific for: WRN (Abcam Inc. and Santa Cruz), c-ABL (EMD Chemicals, Inc.), BCR/ABL (16), P-Tyr, RAD51, RPA70, and RPA32 (Milipore), b-actin, XRCC4, ligase IV, Artemis, XLF, XRCC1, lamin B1 (Abcam Inc.), caspase-3 and ligase III (BD Biosciences), RAD52 and PARP-1 (Cell Signaling Technology, Inc.), Ku70 and Ku80 (AbD Serotec), tubulin (Novus Biologicals), and DNA-PKcs (Thermo Scientific Inc.). Densitometric analysis was done using Quantity One software (Bio-Rad).
WRN enzymatic assays
Helicase and exonuclease activities were determined as described previously with modifications (refs. 21, 22; Supplemental Methods). Reaction samples were subjected to electrophoresis in 14% nondenaturing (helicase) and denaturing (exonuclease) gels, and visualized by autoradiography. The products were quantified using Quantity One software (Bio-Rad).
Retroviral infection
To produce viral supernatants, retroviral DNAs were transiently transfected into Phoenix Amphotropic cells. The viral supernatants were collected 36 hours later, filtered, and concentrated by centrifugation at 20,000 rpm for 2 hours at 14 C. Cells (0.5 Â 10 6 cells/mL) were infected with 1:1 mixture of freshly concentrated virus and medium, twice a day for 2 days in the presence of 4 mg/mL of polybrene (Sigma) as described before (15) .
Genotoxic treatment
Downregulation of WRN was achieved as described by Grandori and colleagues (18) . Briefly, BCR/ABL-positive UT7 and MO7 cells were infected with pBABEpuro-shWRN or with pBABEpuro and selected in puromycin. Furthermore, cells expressing pBABEpuro-shWRN were cotransfected with LXSN-WRN cDNA construct and selected in G418. Downregulation and restoration of WRN expression was confirmed by Western analysis. Cells were treated with increasing doses of H 2 O 2 or g-radiation (
137 Cs) and examined 48 hours and 5 days later by trypan blue exclusion test and clonogenic assay in methylcellulose, respectively, as described before (5, 16, 21) .
Examination of DSB repair
The activities of HRR, NHEJ, and SSA were measured as described before (7, 16, 23) with modifications (Supplemental Methods).
Results
BCR/ABL and other FTKs stimulate the expression of WRN
Our genome-wide array suggested that WRN is overexpressed in CML mononuclear cells by 2.7 AE 1.1-fold in comparison with normal counterparts (21) . To confirm this observation total RNA was isolated from 32D and 32D-BCR/ ABL (32D-B/A) cell lines, and CD34
þ bone marrow cells Fig. 1 ).
To investigate the mechanism of WRN upregulation the transactivation assay was carried out with the use of WRN promoter sequence linked to the luciferase gene. WRN transactivation required BCR/ABL kinase activity; the BCR/ ABL[K1172R] kinase-dead mutant did not exert significant activity (Fig. 1C) . In addition, BCR/ABL kinase-mediated transactivation of WRN was inhibited by c-Myc dominantnegative mutants (DNM) but not by STAT5 DNM. Altogether, it seems that WRN transactivation is mediated at least in part by BCR/ABL kinase-c-Myc pathway.
WRN was degraded in parental cells undergoing apoptosis due to growth factor starvation (Fig. 1D , left box; ref. 24 ). The process is probably caspase(s)-dependent and does not involve proteasomal activity because it was prevented by the pan-caspase inhibitor Z-VAD-FMK but not by the proteasome inhibitor epoxomycin. Expression of BCR/ABL kinase and overexpression of Bcl-xL, a known inhibitor of caspase-3 activation downstream of BCR/ABL kinase prevented WRN degradation (Fig. 1D , left and right box, respectively). Thus, we hypothesize that BCR/ABL kinase-Bcl-xL pathway protects WRN protein from caspase-3-dependent degradation.
Although total cellular WRN levels were stimulated also by IL-3 signaling in normal cells ( Fig. 2A) , BCR/ABL in comparison with IL-3 enhanced nuclear and chromatin localization of WRN by greater than 3.5-fold as determined by densitometric analysis (Fig. 2B) .
BCR/ABL kinase interacts with WRN resulting in its tyrosine phosphorylation and stimulation of the helicase and exonuclease activity
To determine if WRN interacts with BCR/ABL, WRN was immunoprecipitated from 32D-BCR/ABL cells. p210BCR/ABL protein was readily detected in anti-WRN-specific immunoprecipitates (Fig. 3A) ; on the other hand, WRN was present in anti-BCR/ABL-specific immunoprecipitates (Fig. 3B) . WRN immunoprecipitated from 32D-BCR/ABL cells was phosphorylated on tyrosine residue(s) (Fig. 3C ). This effect was abrogated when the cells were treated with the ABL kinase inhibitor imatinib, suggesting that WRN might be a substrate for BCR/ABL kinase.
WRN helicase and exonuclease activities were analyzed in 32D-BCR/ABL cells treated or not treated with imatinib. WRN A B C immunoprecipitates obtained from the cells incubated with 0.5 m mol/L imatinib in the presence of IL-3 displayed 2-to 3-fold reduction of helicase and exonuclease activity in comparison with these obtained from untreated counterparts (Fig. 4A and B, respectively). Thus, BCR/ABL kinase activity stimulated both helicase and exonuclease activities of WRN. Similar amounts of immunoprecipitated WRN from the cells treated or not with imatinib were used for these assays. Although BLM, which may coprecipitate with WRN and exert helicase activity, was not detectable in WRN immunoprecipitates (data not shown), we cannot exclude the potential role of another helicase and/or exonuclease.
WRN protects BCR/ABL-positive cells after DNA damage caused by genotoxic and oxidative stress WRN was downregulated in MO7 parental cells and MO7-BCR/ABL cells by transfection with the plasmid encoding human WRN-specific shRNA as confirmed by Western analysis (Fig. 5A) . WRN-specific shRNA did not significantly affect the proliferation of transfected cells (data not shown). Genotoxic and oxidative stress were induced by g-irradiation and H 2 O 2 and cell survival and proliferation were monitored by trypan blue exclusion and clonogenic assays. As expected MO7-BCR/ABL cells were less sensitive to g-irradiation and H 2 O 2 treatment than parental counterparts (Fig. 5B and C) . Downregulation of WRN increased the sensitivity of MO7-BCR/ABL cells to H 2 O 2 ( Fig. 5B ) and g-irradiation (Fig. 5C ).
Similar effect was also observed in UT7-BCR/ABL leukemia cells (Supplemental Fig. 2 ). Partial restoration of WRN protein levels in MO7-BCR/ABL cells expressing shWRN by cotransfection with a retroviral construct expressing WRN cDNA (Fig. 5D) diminished their sensitivity to H 2 O 2 ( Fig. 5E ) and g-irradiation (Fig. 5F ). Incomplete restoration of WRN expression was probably due to a balance between simultaneous action of the plasmids encoding for overexpression (LXSN-WRN cDNA) and downregulation (pBABEpuro-shWRN) of the protein.
WRN modulates the efficiency of recombinationdependent repair (HRR and SSA) and the fidelity of NHEJ in BCR/ABL-positive cells
We first examined the expression levels of HRR-and SSArelated proteins in MO7 parental cells and MO7-BCR/ABL leukemia cells treated or not with imatinib. Cells were incubated with GM-CSF in concentrations necessary to stimulate proliferation of parental cells. In these conditions BCR/ABLpositive leukemia cells overexpressed HRR-related nuclear RAD51 and imatinib reduced the level of nuclear RAD51 in leukemia cells (Fig. 6A , left box) in concordance with previous report (16) . Expression of HRR-related RPA70 and RPA32 and SSA-related RAD52 and ERCC1 was not affected by BCR/ABL kinase (Fig. 6B, left box) .
To examine HRR and SSA activity, DR-GFP and SA-GFP recombination cassettes containing inactivated GFP gene due to introduction of the unique I-SceI restriction site with 2 stop codons and a truncated version of the gene containing BcgI restriction site was integrated into the genome of MO7 parental and MO7-BCR/ABL cells. A DSB is generated in DR-GFP and SA-GFP cassettes upon transient transfection with I-SceI expression plasmid, which if repaired by HRR and SSA, respectively, could restore a functional GFP gene and GFP protein expression. Cells were transfected with I-SceI and pDsRed1-Mito (transfection efficiency control) expression plasmids and the efficiency of HRR and SSA was measured 48 hours later by scoring the percentage of double-positive
As expected, BCR/ABL stimulated HRR and SSA ( Fig. 6A and B, right boxes; ref. 7, 16) . Downregulation of WRN in MO7-BCR/ABL cells ( Fig. 6A; inset) by previously validated shRNA complementary to human WRN caused approximately 2-and 3-fold inhibition of HRR and SSA, respectively ( Fig. 6A and B,  right) . Similar effect was observed in BCR/ABL-positive Daoy medulloblastoma cells (Supplemental Fig. 3) .
NHEJ usually occurs via DNA-PKcs-dependent (D-NHEJ) classical pathway involving Ku70, Ku80, DNA-PKcs, Artemis, XLF, ligase IV-XRCC4 proteins, and via backup pathway (B-NHEJ) exerted by PARP-1, XRCC1, and ligase III (25) . Although BCR/ABL-positive leukemia cells and parental counterparts display similar levels of nuclear Ku70, Ku80, XRCC1, and XRCC4 proteins in the presence of growth factors, DNA-PKcs was downregulated, and Ligase IV, Artemis, XLF, PARP-1, and ligase III were upregulated (Fig. 7A) .
To study the role of WRN in NHEJ, we used the in vitro assay as described before (26) . The in vivo assay measuring NHEJ activity and fidelity with the use of DR-GFP cassette should not be used here because downregulation of WRN may affect also Mre11, an exonuclease upregulated by BCR/ABL kinase that promotes deletional NHEJ (27) (28) (29) . Because a majority of DSBs generated by ROS and g-irradiation do not have ligatable termini, pBluescript plasmid linearized by XhoI þ XbaI digestion creating noncomplementary 3' and 5' overhangs was used as the substrate to assess the activity of NHEJ. The synapsed DNA ends must be processed before ligation during NHEJ to generate multimers of plasmid. We used this substrate because WRN interacted with it (30). The substrate was added to nuclear cell lysates from 32D parental and 32D-BCR/ABL cells, in which WRN was immunodepleted or not by specific antibody (Fig. 7B, inset) . The 32D-BCR/ABL cells were used here because of the very efficient immunodepletive capability of the anti-WRN antibody in murine cell lysates. As expected (23) BCR/ABL stimulated NHEJ by approximately 3-fold and immunodepletion of WRN did not affect NHEJ activity in lysates from 32D-BCR/ABL cells (Fig. 7B ). In concordance with our previous report (23) , the presence of BCR/ABL promoted larger deletions in some NHEJ products (3/8 products averaged loss of 29 AE 4.35 bases; 5/8 products averaged loss of 3.8 AE 2.17 bases; Fig. 7C , Supplemental  Fig. 4) . Overall, NHEJ products catalyzed by 32D-BCR/ABL lysates lost on average 13.25 AE 13.35 bases. Large deletions were not detected in NHEJ product catalyzed by 32D parental cells (average loss of 3.29 AE 1.9 bases). Immunodepletion of WRN prevented larger deletions in NHEJ products catalyzed by 32D-BCR/ABL lysates, which averaged 1.43 AE 1.27 bases lost.
Discussion
To protect the leukemia cells from excessive ROS-and genotoxic agent-induced DSBs, BCR/ABL kinase stimulates HRR, NHEJ, and SSA at the cost of repair fidelity (6, 7, 23) . These repair mechanisms require the presence of WRN, which plays a critical role in optimizing DSB repair mechanisms due to its DSB end-processing helicase and exonuclease activities (30) .
Our results suggest that BCR/ABL and other FTKs stimulate WRN expression in part by c-Myc-induced transactivation and Bcl-xL-dependent inhibition of caspase-mediated cleavage. The involvement of c-Myc is supported by the presence of several noncanonical Myc-Max binding sites in WRN promoter (18) . WRN contains putative caspase-3 binding sites (31) , thus explaining the potential protective role of caspase inhibitor Z-VAD-FMK and antiapoptotic protein Bcl-xL, which prevents caspase-3 activation in BCR/ABLpositive cells (32) . More abundant stimulation of WRN protein (6.9-fold) than mRNA (2.7-fold) expression is also BCR/ABL kinase forms a complex with WRN protein resulting in its constitutive tyrosine phosphorylation and also activates WRN helicase and exonuclease activity. In addition, elevated expression of WRN in leukemia cells was associated with enhanced nuclear and chromatin localization, which is essential in response to DNA damage (33, 34) .
Cheng and colleagues reported that WRN formed a complex with c-ABL and that ABL-mediated tyrosine phosphorylation of WRN resulted in inhibition of its helicase and exonuclease activities (22) . As c-ABL interacts directly with the exonuclease and helicase domains of WRN, its excessive presence in the in vitro reaction mixture might promote prolonged interaction, which will physically block the domains of WRN responsible for its enzymatic activities. In fact, results from stoichiometric experiments showed that inhibition of WRN helicase and exonuclease activities in vitro is c-ABL proteindosage dependent, and not phosphorylation-dependent phenomenon. However, the in vivo stoichiometric conditions may promote BCR/ABL-WRN complex formation and WRN phosphorylation, followed by complex disassembly and migration of preactivated WRN to the nucleus.
BCR/ABL-mediated regulation of WRN expression, localization, and activity may exert a profound impact on the response to elevated levels of ROS-and genotoxic agentinduced DSBs in CML CD34 þ stem/progenitor cells (7) . Using shRNA to downregulate WRN, we showed that WRN promotes the survival of BCR/ABL-positive leukemia cells under oxidative and genotoxic stress, in concordance with other reports from solid tumors (11, 12, 14, 35) . This effect may depend on the capability of WRN to facilitate the repair of numerous DBSs in leukemia cells (6, 7, 16) . As BCR/ABL stimulates unfaithful DSB repair mechanisms (6-9, 23, 36) , WRN, in opposite to normal cells (10) , may promote genomic instability in CML-CP. Our studies showed that BCR/ABL and other FTKs, such as TEL/ABL, TEL/JAK2, TEL/PDGFbR, and NPM/ALK, stimulate recombination-dependent DSB repair: RAD51-mediated HRR and RAD52-mediated SSA (5, 7). Although HRR normally act to maintain genetic stability, if overstimulated, it can produce intra-and interchromosomal deletions, chromosomal translocations, and aneuploidity (37) . In addition, point mutations can be accumulated in HRR products (6) . When sequence repeats (e.g., Alu) are present near DSBs, they can undergo SSA, resulting in intrachromosomal deletions and chromosomal translocations (38) .
Results presented here suggest that WRN is essential for enhanced activity of unfaithful HRR and SSA in BCR/ABLtransformed cells, thus implicating WRN in genomic instability in CML. In support to these findings, WRN interacts with RAD51, a key mediator of HRR responsible for initial pairing and strand exchange, which is upregulated by BCR/ABL (16, 39) . Moreover, WRN interacts with RAD52, which enhances its helicase activity and increases the efficiency of RAD52-mediated strand annealing (40) .
We and others also reported that BCR/ABL kinase facilitates NHEJ and promote more extensive deletions in about 35% of repair products (6, 8, 23) . NHEJ has an important function in maintaining genomic integrity but not necessarily the fidelity because it may rejoin DSBs in a nonconservative manner and usually some genetic information is lost (41) . Accordingly, stimulation of NHEJ may increase the risk of accumulation of genetic aberrations including these in quiescent cells (42) .
We show that WRN did not regulate the efficiency of NHEJ in BCR/ABL-positive leukemia cells but it caused excessive loss of bases in the repair products. In normal cells, WRN did not affect, or even reduced, deletions (depending on the DSB ends) in NHEJ products (30) . However, the properties of WRN and the intracellular environment in CML cells are substantially altered in comparison with normal cells. Not only BCR/ ABL kinase stimulates the expression, tyrosine phosphorylation, and nuclear localization of WRN, but it also enhances WRN helicase and exonuclease activity. In addition, WRN exerts its function in the context of modified expression of other proteins involved in NHEJ, which may have a substantial impact on WRN properties. It seems that proteins responsible for D-NHEJ are deregulated by BCR/ABL: nuclear DNA-PKcs was downregulated, whereas ligase IV, Artemis, and XLF were upregulated by BCR/ ABL kinase, but XRCC4, Ku70, and Ku80 were not changed, which may affect the activity of WRN. Ku70-Ku80 and XRCC4-ligase IV complexes activate WRN exonuclease activity [Ku enables the WRN exonuclease to digest through regions of DNA containing 8-oxoA and 8-oxoG, which are frequent in CML cells (4, 6) ], whereas DNA-PKcs phosphorylates WRN to inhibit its exonuclease and helicase activity (43) (44) (45) . Thus, we postulate that a combination of BCR/ABL-mediated tyrosine phosphorylation of WRN in the presence of Ku70-Ku80 and/or XRCC4-ligase IV and the absence of DNA-PKcs may be responsible for prolonged WRN helicase and/or exonuclease activity causing large deletions during NHEJ. Our hypothesis is supported by the reports that downregulation of DNA-PKcs in CML cells was also reported by others (46) and that extensive deletions were associated with inhibition of DNA-PKcs in advanced bladder carcinoma and chemotherapy resistant B-cell chronic lymphocytic leukemia (47, 48) .
On the other hand, PARP-1 and ligase III are overexpressed in BCR/ABL cells implicating enhanced activity of a backup pathway (B-NHEJ) in concordance with the report by Sallmyr and colleagues (49) . WRN interacts with PARP-1 and seems to play a role in B-NHEJ (50) . Thus, we cannot exclude the possibility that the absence of DNA-PKcs promotes a switch from Ku70-Ku80-initiated D-NHEJ to B-NHEJ on the DSBs that were already extensively processed by WRN, thus resulting in larger deletions. This hypothesis is supported by the report that NHEJ-mediated large deletions in CML-CP cells might depend on the presence of Ku70-Ku80, but not DNA-PKcs (8).
However, extensive secondary genetic and epigenetic aberrations in more advanced CML-BC cells may affect WRN properties (22, 49) . For example, although WRN expression was stimulated, its enzymatic activities were inhibited and its role in NHEJ was altered in CML-BP cell line K562.
In conclusion, we postulate that BCR/ABL kinase-dependent stimulation of the expression, nuclear localization, phosphorylation, and helicase/exonuclease activity of WRN affects all major DSB repair pathways: enhances the activity of unfaithful recombination repair (HRR and SSA) and increases the infidelity of NHEJ. These effects may have a profound impact on leukemia cell survival and accumulation of additional genetic aberrations in CML cells containing numerous DSBs induced by ROS and genotoxic treatment (6, 26, 36) , thus implicating WRN in malignant progression of the disease. BCR/ABL-WRN interaction may become an attractive target for therapeutic intervention preventing malignant progression of CML-CP to CML-BP.
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